MNPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MNPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Monopar Therapeutics's other current assets for the quarter that ended in Mar. 2024 was $0.12 Mil.
Monopar Therapeutics's quarterly other current assets declined from Sep. 2023 ($0.07 Mil) to Dec. 2023 ($0.07 Mil) but then increased from Dec. 2023 ($0.07 Mil) to Mar. 2024 ($0.12Mil).
Monopar Therapeutics's annual other current assets declined from Dec. 2021 ($0.22 Mil) to Dec. 2022 ($0.05 Mil) increased from Dec. 2022 ($0.05 Mil) to Dec. 2023 ($0.07 Mil).
The historical data trend for Monopar Therapeutics's Other Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Other Current Assets | Get a 7-Day Free Trial | 0.02 | 0.06 | 0.22 | 0.05 | 0.07 |
Monopar Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Other Current Assets | Get a 7-Day Free Trial | 0.11 | 0.11 | 0.07 | 0.07 | 0.12 |
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
The assets grouped under other current assets are most commonly:
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
Thank you for viewing the detailed overview of Monopar Therapeutics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J Brown | director | C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211 |
Arthur J Klausner | director | ONE PALMER SQUARE, PRINCETON NJ 08542 |
Raymond Anderson | director | C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Kim R Tsuchimoto | officer: Chief Financial Officer | C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Chandler Robinson | director, officer: Chief Executive Officer | C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Andrew Cittadine | officer: Chief Operating Officer | C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091 |
Patrice Rioux | other: Acting Chief Medical Officer | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Christopher M Starr | director | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Filho Jose Octavio Pinto Costa | officer: Chief Medical Officer | C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091 |
Tactic Pharma Llc | 10 percent owner | C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Diane Hendricks | 10 percent owner | C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801 |
Karl Leo | 10 percent owner | C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801 |
Kirsten Anderson | officer: SVP, Clinical Development | C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Gem Pharmaceuticals Llc | 10 percent owner | C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Tacticgem Llc | 10 percent owner | 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
From GuruFocus
By Value_Insider Value_Insider • 10-27-2022
By Marketwired • 08-10-2023
By sperokesalga sperokesalga • 02-27-2023
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 03-27-2023
By Stock market mentor Stock market mentor • 01-18-2023
By PurpleRose PurpleRose • 07-11-2022
By Marketwired • 07-11-2023
By sperokesalga sperokesalga • 06-01-2023
By Value_Insider Value_Insider • 12-12-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.